Iovance Biotherapeutics, Inc.
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
Last updated:
Abstract:
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed. Also disclosed is the use of IP-10 as a biomarker for predicting treatment efficacy.
Status:
Grant
Type:
Utility
Filling date:
5 Dec 2018
Issue date:
6 Sep 2022